A prospective investigation of the effect with Lomerizine on visual field damage in eyes with glaucoma

A prospective investigation of the effect with Lomerizine on visual field damage in eyes with glaucoma - The effect with Lomerizine on visual field damage

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003182

Enrollment

100

Registered

2010-02-17

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Intervention group. Period 3years, Amount Lomerizine hydrochloride 5mg, Frequency 2 times per day Control group. Period 3years, Amount methylcobalamin 500ug, Frequency 3 times per day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Open angle glaucoma. 2. IOP with anti-glaucoma eye drops not exceeding 17mmHg.

Exclusion criteria

Exclusion criteria: 1. Having history of severe diabetes mellitus and cardiac disease etc. 2. Having administration of calcium channel blocker. 3. Having ocular diseases other than glaucoma. 4. Having history of intraocular surgery and laser surgery within 12 months.

Design outcomes

Primary

Measure	Time frame
visual field	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026